Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Facing thousands of lawsuits related to its talc-based products, life sciences giant Johnson & Johnson is launching a separate subsidiary dubbed LTL Management LLC that will take the brunt of potential legal liabilities.
It was yet another busy week for clinical trial announcements. Take a look.
Genomics veteran Bob Ragusa is taking over GRAIL, a newly-acquired business unit of Illumina, Inc. He is taking over as CEO Hans Bishop steps down from his role.
On Thursday, Tentarix Biotherapeutics announced that it earned $50 million in a Series A financing round, which was co-led by Versant Ventures and Samsara BioCapital.
According to CNN, Califf is being vetted by the administration of Joe Biden, who served as vice president to Obama.
Biopharma and life sciences companies strengthen their leadership teams and executive boards with these Movers & Shakers.
On October 6, 2021, Bristol Myers Squib and Celgene terminated the original deal related to Abraxane and gave BeiGene 180 days of notice that it was withdrawing Abraxane from the deal.
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
Transition Bio named Gregory Miller as chief executive officer, Prof. Tuomas Knowles as chief technology officer and Martin Kulander as chief operating officer, among several others.
Broad announced that it is bringing René Salazar on board as its first chief equity officer.